Human medicines European public assessment report (EPAR): Cabometyx , cabozantinib, Carcinoma, Renal Cell;Carcinomas, Hepatocellular, Date of authorisation: 09/09/2016, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Cabometyx , cabozantinib, Carcinoma, Renal Cell;Carcinomas, Hepatocellular, Date of authorisation: 09/09/2016, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Lupus Erythematosus, Systemic, Date of authorisation: 14/02/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Lupus Erythematosus, Systemic, Date of authorisation: 14/02/2022, Revision: 3, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness